Why is the Telix Pharmaceuticals (ASX:TLX) share price plunging 14%?

What's going on with the ASX 200 biotech's share price today?

| More on:
man grimaces next to falling stock graph

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Telix Pharmaceuticals share price has fallen nearly 14% to trade at $4.09 at the time of writing
  • The fall comes despite analysts' believing the company's stock is worth looking at
  • The market has heard price sensitive news from the company twice this week. However, it seemingly wasn't enough to turn its share price's ongoing tumble around

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is cratering today despite the company's silence.

The plunge follows yesterday's tumble that saw the biotech stock close 7.42% lower.

At the time of writing, the Telix Pharmaceuticals share price is $4.09, 13.71% lower than its previous close.

For context, the S&P/ASX 200 Index (ASX: XJO) is currently up 0.45%.

The company's fall comes despite analysts at Wilsons flagging they're still bullish on the company. They've noted its a stock worth looking at, reports The Motley Fool Australia's Tony Yoo.

So, without further ado, let's take a look at what could be weighing on the ASX 200 newbie's shares on Friday.

What's dragging on the Telix Pharmaceuticals share price?

The Telix Pharmaceuticals share price is in the red once more today despite no news having been released by the company. However, the market did hear from it on both Tuesday and Wednesday.

First, the company announced that the buildout of its Beligian radiopharmaceutical production facility has begun.

To fund the development, the company has secured an $18.2 million loan and applied for $3 million of grants. The first stage of the build is expected to cost $21.2 million.

Then, it released news its glioblastoma multiforme therapy candidate TLX101 has progressed to the next stage of clinical development – a phase 1 dose escalation study.

The Telix Pharmaceuticals share price gained 1.4% on Tuesday and 2.2% on Wednesday, before plummeting towards the end of the week.

It's a similar story to the recent performance of the S&P/ASX 200 Health Care Index (ASX: XHJ). It fell 0.61% yesterday and it's currently down another 0.71%. Telix Pharmaceuticals is the sector's weight today.

Also worth noting, the company's short-selling interest has risen from approximately 1% this time last month to 2.25% as of the most recent data. That means more market participants are expecting the stock to go lower.

So far since last Friday's close, the company's stock has tumbled nearly 20%. It's worth noting, it gained 4.5% last week.

Though, the Telix Pharmaceuticals share price is likely used to being in the red. It has fallen 50% since the start of 2022. Still, it's only 9% lower than it was this time last year.

That's despite the company taking the place of the formerly-listed Sydney Airport in the ASX 200 in February.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »